Sugi Predict

Sugi Predict / Compounds / SCHEMBL1146715

SCHEMBL1146715

SCHEMBL1146715

O=C(O)c1ccc(C(=O)CF)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 3/20 0.60
▸ TP53 P04637 1/20 0.60
▸ SRD5A2 P31213 5/20 0.52
▸ CA1 P00915 2/20 0.50
▸ CA2 P00918 2/20 0.50
▸ CA12 O43570 1/20 0.50
▸ CA3 P07451 1/20 0.50
▸ TYR P14679 1/20 0.50
▸ DRD1 P21728 1/20 0.50
▸ CA4 P22748 1/20 0.50
▸ CA6 P23280 1/20 0.50
▸ CA5A P35218 1/20 0.50
▸ CA7 P43166 1/20 0.50
▸ CA9 Q16790 1/20 0.50
▸ CA14 Q9ULX7 1/20 0.50
▸ CA5B Q9Y2D0 1/20 0.50
▸ ALDH1A1 P00352 3/20 0.48
▸ BCL2L1 Q07817 1/20 0.48
▸ BAD Q92934 1/20 0.48
▸ ALOX15 P16050 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL157987 0.82 TDP1 (0.64) TSHRALDH1A1ALOX15SMN1; SMN2DAO
SCHEMBL27980420 0.82 TDP1 (0.64) TSHRALDH1A1ALOX15SMN1; SMN2DAO
Terephthalic Acid SCHEMBL1006723 0.81 TSHR (0.92) TSHRTP53SRD5A2CA1CA2
Hydrochloric Acid SCHEMBL7418291 0.80 TDP1 (0.61) TSHRALDH1A1ALOX15SMN1; SMN2DAO
SCHEMBL9909660 0.80 PTPN1 (0.41) ALDH1A1ALOX15SMN1; SMN2CES1
SCHEMBL11571 0.80 NPC1 (0.64) CA1CA2BCL2L1BADSMN1; SMN2
SCHEMBL310879 0.80 NPC1 (0.60) CA1CA2CA12CA3TYR
SCHEMBL13715444 0.79 SMN1; SMN2 (0.64) SRD5A2ALDH1A1SMN1; SMN2
SCHEMBL28594420 0.79 TSHR (0.67) TSHRTP53SRD5A2CA1CA2
SCHEMBL743683 0.78 TPMT (0.52) CA1CA2TPMT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12378209-B2 Protease inhibitors MEDIVIR AB (SE) 2025-08-05 — — US disclosed
US-20220332690-A1 PROTEASE INHIBITORS MEDIVIR AB (SE) 2022-10-20 — — US disclosed
CN-107922347-B Novel imide derivatives and their use as pharmaceuticals 田边三菱制药株式会社 2022-06-28 — — CN disclosed
US-11312693-B2 Protease inhibitors MEDIVIR AB (SE) 2022-04-26 — — US disclosed
US-20210017140-A1 PROTEASE INHIBITORS MEDIVIR AB (SE) 2021-01-21 — — US disclosed
US-10723709-B2 Protease inhibitors MEDIVIR AB (SE) 2020-07-28 — — US disclosed
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 — — US disclosed
US-10329266-B2 Protease inhibitors MEDIVIR AB (SE) 2019-06-25 — — US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 — — US disclosed
US-20180327371-A1 PROTEASE INHIBITORS MEDIVIR AB (SE) 2018-11-15 — — US disclosed
EP-2350089-A1 PROTEASE INHIBITORS Medivir AB (SE) 2011-08-03 — — EP disclosed
EP-2331548-A1 PROTEASE INHIBITORS Medivir AB (SE) 2011-06-15 — — EP disclosed
US-20110105524-A1 CYSTEINE PROTEASE INHIBITORS MEDIVIR AB (SE) 2011-05-05 — — US disclosed
US-7893067-B2 Cysteine protease inhibitors MEDIVIR AB (SE) 2011-02-22 — — US disclosed
US-20110039862-A1 Protease Inhibitors MEDIVIR AB (SE) 2011-02-17 — — US disclosed
WO-2010034788-A1 PROTEASE INHIBITORS MEDIVIR AB (SE) 2010-04-01 — — WO disclosed
WO-2010034789-A1 PROTEASE INHIBITORS MEDIVIR AB (SE) 2010-04-01 — — WO disclosed
EP-2167507-A1 CYSTEINE PROTEASE INHIBITORS Medivir AB (SE) 2010-03-31 — — EP disclosed
US-20090023748-A1 Cysteine Protease Inhibitors MEDIVIR AB (SE) 2009-01-22 — — US disclosed
WO-2009000877-A1 CYSTEINE PROTEASE INHIBITORS MEDIVIR AB (SE) 2008-12-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10723709-B2 Protease inhibitors CTSK, CTSF, CTSS TSHR 1000/4885TP53 858/4885SRD5A2 2226/4885
US-11312693-B2 Protease inhibitors CTSK, CTSF, CTSS TSHR 1000/4885TP53 858/4885SRD5A2 2226/4885
US-20110105524-A1 CYSTEINE PROTEASE INHIBITORS CTSK, CTSL, CTSV TSHR 1544/4885TP53 406/4885SRD5A2 3476/4885
US-10329266-B2 Protease inhibitors CTSK, CTSF, CTSS TSHR 1000/4885TP53 858/4885SRD5A2 2226/4885
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MMP9, MMP10, MMP1 TSHR 3522/4885TP53 4082/4885SRD5A2 2668/4885
US-20090023748-A1 Cysteine Protease Inhibitors CTSK, CTSL, CTSV TSHR 1544/4885TP53 406/4885SRD5A2 3476/4885
US-12378209-B2 Protease inhibitors MMP26, CTSK, TMPRSS6 TSHR 891/4885TP53 858/4885SRD5A2 2114/4885
US-20210017140-A1 PROTEASE INHIBITORS CTSK, CTSF, CTSS TSHR 1000/4885TP53 858/4885SRD5A2 2226/4885
US-20110039862-A1 Protease Inhibitors CTSK, CTSF, CTSS TSHR 984/4885TP53 829/4885SRD5A2 2205/4885
US-10407408-B2 Imide derivatives and use thereof as medicine MMP9, MMP2, MMP1 TSHR 3141/4885TP53 3806/4885SRD5A2 2568/4885
US-20180327371-A1 PROTEASE INHIBITORS CTSK, CTSF, CTSS TSHR 1000/4885TP53 858/4885SRD5A2 2226/4885
US-20220332690-A1 PROTEASE INHIBITORS MMP26, CTSK, TMPRSS6 TSHR 891/4885TP53 858/4885SRD5A2 2114/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.